• OPEN AN ACCOUNT
Indian Indices
Nifty
22,466.10 62.25
(0.28%)
Sensex
74,005.94 88.91
( 0.12%)
Bank Nifty
48,115.65 138.60
( 0.29%)
Nifty IT
33,381.85 -286.60
( -0.85%)
Global Indices
Nasdaq
16,685.97 -12.35
(-0.07%)
Dow Jones
40,003.59 134.21
(0.34%)
Hang Seng
19,553.61 177.08
(0.91%)
Nikkei 225
38,787.38 -132.88
(-0.34%)
Forex
USD-INR
83.47 0.01
(0.01%)
EUR-INR
90.76 0.22
(0.25%)
GBP-INR
105.79 0.36
(0.34%)
JPY-INR
0.54 0.00
(0.51%)

EQUITY - MARKET SCREENER

Jubilant Pharmova Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
530019
INE700A01033
146.9008161
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
JUBLPHARMA
0
11467.21
EPS(TTM)
Face Value()
Div & Yield %
0
1
0.69
 

jubilant life sciences ltd
Jubilant Cadista Pharmaceuticals to close down manufacturing operations
Apr 18,2024
Jubilant Pharmova announced that the company's subsidiary, Jubilant Cadista Pharmaceuticals Inc., USA has decided to close the manufacturing operations of its solid dosage formulation facility at Salisbury, Maryland, USA. The expected date of cessation of manufacturing operation and first separations at the said facility will be on 17 June 2024. Jubilant Cadista will continue the sales and marketing operations for US market. The said facility manufactures tablets and capsules for the US market and has the capacity to serve 1.5 billion doses.

Jubilant Cadista is a subsidiary of Jubilant Pharma Holdings Inc., USA, which is held by Jubilant Pharma, Singapore, a wholly owned subsidiary of the Company.

Over the last few years the US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.

In order to move the US generics business to profitability, it has been decided to change the operating model from in-house manufacturing to outsourced manufacturing by selected USFDA approved CMOs for the US market.

Further, following the status change of Jubilant Generics Limited's (‘JGL') Roorkee facility by USFDA to VAI, the company expects the exports from the Roorkee facility to the US market to increase in a meaningful and gradual manner. As of now the facility, was exporting only one product, Risperidone to the US market. JGL is a subsidiary of Jubilant Pharma Ltd, a wholly owned subsidiary of the company.

These actions are expected to improve the gross margins of the Generics business by reducing manufacturing, quality management and overhead costs, which will drive the generics business towards profitability. Lastly, the Generics business has plans to scale up revenues in the US market through launch of new products.

Jubilant Cadista shall continue to explore various options to utilize or sell the said facility's Land, Building and Plant & Machinery in the due course.